India firm shakes up cancer drug market with price cuts

June 17, 2012 by Penny MacRae

Indian pharmaceutical tycoon Yusuf Hamied revolutionised AIDS treatment more than a decade ago by supplying cut-price drugs to the world's poor -- and now he wants to do the same for cancer.

Hamied, chairman of generic drugs giant Cipla, last month slashed the cost of three medicines to fight brain, kidney and in India, making the drugs up to more than four times cheaper.

"I hope we'll cut prices of many more ," he told AFP, adding that he wants to supply the cheaper drugs to Africa and elsewhere.

"Reducing the price of cancer drugs is a humanitarian move."

Hamied, 76, was pilloried by Western drug giants 11 years ago when he broke their monopoly by offering to supply life-saving triple therapy cocktails for under $1 a day -- one-thirtieth the price of the multinationals.

The firms branded him an intellectual property thief while he accused them of being "global serial killers" whose high prices were costing the lives of .

"What he did was path-breaking. It has been very important in saving lives, and what he is doing with cancer drugs is the same," said Leena Menghaney, a lawyer with humanitarian group Medecins sans Frontieres (Doctors Without Borders).

In 1972, India made only the process for making drugs patentable, not the drugs themselves.

This meant firms could "reverse-engineer" or change methods used to make medicines and sell them at up to one-fiftieth of US prices.

The legislation gave a huge leg-up to India's generics industry and gave the nation the nickname "the pharmacy to the Third World".

But in 2005, India brought its law in line with (WTO) rules recognising 20-year patents, pushing up the prices of newly launched drugs.

Cipla, India's fourth largest pharmaceutical company by sales, has been pressing the government to allow widespread use of "compulsory licences", which are permitted under WTO rules.

The licences allow companies to make existing life-saving drugs to sell in countries where they are otherwise priced out of reach.

India's first such licence was granted in March to Natco Pharma to produce a generic version of Bayer's blockbuster kidney cancer Nexavar, cutting the price from 28,000 rupees ($500) for a monthly dose to 6,840 rupees.

Ranjit Shahani, who heads the Organisation of Pharmaceutical Producers of India, says widespread compulsory licensing will jeopardise investment in innovative pharmaceuticals.

Bayer has said it will launch a legal challenge to the compulsory licence, and global drugmakers have vowed to oppose the spread of such legislation.

Hamied denied that his latest move was simply an attempt to boost his share in the oncology drugs market, insisting business must be linked to "social responsibility".

But he said like any other business his company, which has 23 cancer drugs, also wants higher sales.

"I owe it to my shareholders to be pragmatic," he said.

Born in Lithuania to an Indian Muslim father and a Lithuanian Jewish mother, Hamied was two months old when his parents fled Europe in the 1930s under the threat of Nazi Germany.

He was raised in Mumbai and studied for a doctorate in chemistry at Cambridge University in Britain before joining Cipla, which was founded by his father.

"My father never forced me but chemistry was my best subject," said Hamied, who became chairman of the company in 1989.

His bold step in offering cheap AIDS drugs turned out to be a smart business move.

Cipla is now the world's largest AIDS antiretroviral drugs supplier and the publicly-listed company is valued at nearly $5 billion, while business magazine Forbes puts Hamied's personal fortune at $1.75 billion.

But Hamied said poverty-racked India "can't afford to divide people into those who can afford life-saving drugs and those who can't".

"It needs a pragmatic policy," he said.

He believes the pharma giants should let emerging market drugmakers make copycat medicines in exchange for small royalties.

Some 95 percent of Western firms' profits come from regulated developed markets like Japan, Europe, America, so the pharmaceutical giants "really won't lose out", he said.

Even with the reduced price of , such medicines are still beyond the reach of many of the world's poorest, conceded Hamied, who confesses he has his eye on his legacy.

"I want it to be said when I leave this world that 'he was not just a money-making machine,'" he said.

Explore further: Indian drug giant Cipla slashes cancer drug prices

Related Stories

Indian drug giant Cipla slashes cancer drug prices

May 4, 2012
Indian drugs giant Cipla said Friday it has slashed by up to 76 percent prices of generic medicines used to treat brain, lung and kidney cancer in what the company called a "humanitarian move".

Bayer mulls challenge to India cancer drug ruling

March 13, 2012
Bayer AG said Tuesday it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant.

Bayer challenges India cancer drug ruling

May 6, 2012
German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

India patent case threatens cheap drug supply: MSF

September 5, 2011
Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.

India licenses generic copy of patented Bayer drug

March 12, 2012
(AP) -- India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable.

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.